Please wait while the formulary information is being retrieved.
IFEX (IFOSFAMIDE)
- Testicular germ cell tumor
- Ifosfamide Iv Solution
- Ifosfamide Intravenous Powder For Solution
- Ifex Iv Solution
- Ifex Intravenous Solution
- By Indication
1 gram intravenous solution
- Infuse 1,200 mg/m2 by intravenous route once daily for 5 days
3 gram intravenous solution
- Infuse 1,200 mg/m2 by intravenous route once daily for 5 days
1 gram intravenous solution
- Infuse 1,200 mg/m2 by intravenous route once daily for 5 days
3 gram intravenous solution
- Infuse 1,200 mg/m2 by intravenous route once daily for 5 days
1 gram intravenous solution
- Infuse 1,200 mg/m2 by intravenous route once daily for 5 days
3 gram intravenous solution
- Infuse 1,200 mg/m2 by intravenous route once daily for 5 days
1 gram intravenous solution
- Infuse 1,200 mg/m2 by intravenous route once daily for 5 days
3 gram intravenous solution
- Infuse 1,200 mg/m2 by intravenous route once daily for 5 days
Burkitt's lymphoma
- Infuse 1,500 mg/m2 by intravenous route once daily for 5 days
Ewing's sarcoma
- Infuse 2,000 mg/m2 by intravenous route once daily for 3 days
- Infuse 1,800 mg/m2 by intravenous route once daily for 5 days
- Infuse 3,000 mg/m2 by intravenous route once daily for 3 days
- Infuse 3,000 mg/m2 by intravenous route once daily on days 1, 2, 22, 23, 43, and 44 of treatment cycle
Invasive bladder malignancy
- Infuse 1,500 mg/m2 by intravenous route once daily for 5 days
Osteosarcoma of bone
- Infuse 2,000 mg/m2 by intravenous route once daily for 3 days
- Infuse 1,800 mg/m2 by intravenous route once daily for 5 days
- Infuse 3,000 mg/m2 by intravenous route once daily for 5 days
Progressive diffuse large b-cell lymphoma
- Infuse 1,000 mg/m2 by intravenous route once daily
- Infuse 1,000 mg/m2 by intravenous route once daily for 3 days
- Infuse 5,000 mg/m2 over 24 hour(s) by continuous infusion route every2 weeks beginning on day 4 of cycle
Soft or connective tissue sarcoma
- Infuse 1,500 mg/m2 by intravenous route once daily for 4 days
- Infuse 2,000 mg/m2 by intravenous route once daily for 4 days
- Infuse 2,000 mg/m2 by intravenous route once daily for 3 days
- Infuse 1,800 mg/m2 by intravenous route once daily for 5 days
- Infuse 3,000 mg/m2 by intravenous route once daily for 3 days
Testicular germ cell tumor
- Infuse 1,500 mg/m2 by intravenous route once daily for 4 days
- Infuse 2,000 mg/m2 by intravenous route once daily for 4 days
- Infuse 1,200 mg/m2 by intravenous route once daily for 5 days
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Acute confusion
- Coma
- Lactating mother
Contraindicated
- Anemia
- Chemotherapy-induced hemorrhagic cystitis
- Dehydration
- Fanconi syndrome
- Hypokalemia
- Kidney disease with reduction in GFR
- Leukopenia
- Pregnancy
- Renal tubular acidosis
- Thrombocytopenic disorder
Severe
Moderate
- Abnormal hepatic function tests
- Bone metastases
- Disease of liver
- Hyperbilirubinemia
- Impaired wound healing
- Kidney excision
- Polyneuropathy
IFEX (IFOSFAMIDE)
- Testicular germ cell tumor
- Anemia
- Drug-induced hepatitis
- Dysuria
- Hemorrhagic cystitis
- Increased urinary frequency
- Infection
- Leukopenia
- Neutropenic disorder
- Thrombocytopenic disorder
- Alopecia
- Drowsy
- Hematuria
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Acute confusion
- Nephrotoxicity
- Fever
- Phlebitis after infusion
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal ECG
- Acute leukemia
- Acute myocardial infarction
- Agranulocytosis
- Anaphylaxis
- Angioedema
- Atrial fibrillation
- Auditory neurotoxicity
- Bacterial sepsis
- Bundle branch block
- Capillary leak syndrome
- Cardiomyopathy
- Cardiotoxicity
- Chemotherapy-induced hyperuricemia
- Chronic heart failure
- CNS toxicity
- Coma
- Deep venous thrombosis
- Disseminated intravascular coagulation
- Drug-induced psychosis
- Dyspnea
- Encephalopathy
- Extrapyramidal disease
- Fibrosis of pericardium
- Hallucinations
- Hemolytic uremic syndrome
- Hepatic veno-occlusive disease
- Herpes zoster
- Hypertension
- Hypotension
- Immunosuppression
- Interstitial pneumonitis
- Malignant lymphoma
- Metabolic acidosis
- Methemoglobinemia
- Multiple organ failure
- Myelodysplastic syndrome
- Nephrogenic diabetes insipidus
- Opportunistic fungal infection
- Opportunistic viral infection
- Pericardial effusion
- Pneumocystis jirovecii pneumonia
- Polyneuropathy
- Premature atrial contractions
- Progressive multifocal leukoencephalopathy
- Pulmonary fibrosis
- Pulmonary thromboembolism
- Radiation recall syndrome
- Renal cell carcinoma
- Secondary acute myeloid leukemia
- Seizure disorder
- Septic shock
- Severe bone marrow depression
- SIADH syndrome
- Stomatitis
- Supraventricular arrhythmias
- Supraventricular tachycardia
- Thyroid carcinoma
- Vasculitis
- Ventricular arrhythmias
- Ventricular premature beats
- Ventricular tachycardia
Less Severe
- Acute abdominal pain
- Amenorrhea
- Angina
- Anorexia
- Azoospermia
- Blurred vision
- Chills
- Conjunctivitis
- Constipation
- Delirium
- Fatigue
- Flushing
- Hearing loss
- Impaired wound healing
- Infertility
- Malaise
- Memory impairment
- Oligospermia
- Panic disorder
- Peripheral neuropathy
- Polydipsia
- Polyuria
- Premature menopause
- Pruritus of skin
- Sialorrhea
- Skin inflammation
- Skin pigmentation enhancement
- Tinnitus
- Urinary incontinence
- Urticaria
- Vertigo
Contraindicated
None
Severe Precaution
Ifosfamide
Pre-pubescent males may be at risk for under-developed secondary sexual characteristics and females at risk for impaired ovarian function.
- 1 Day – 18 Years
- Pre-pubescent males may be at risk for under-developed secondary sexual characteristics and females at risk for impaired ovarian function.
Management or Monitoring Precaution
None
Ifosfamide
- Severity Level:
D
- Additional Notes: Available human data suggest increased risk of developmental toxicity.
Contraindicated
Ifosfamide
Not recommended, potential severe toxicity. tumorigenic in animal studies.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Not recommended, potential severe toxicity. tumorigenic in animal studies. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Ifosfamide
Renal-Impairment may predispose patients to increased incidence of CNS, hematologic and renal toxicities.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Ifosfamide may cause serious (even fatal) side effects (including urinary problems such as hemorrhagic cystitis, mental/mood changes, blood/bone marrow disorders), which may require your treatment with this medication to be stopped. Tell your doctor right away if you develop symptoms such as pink/bloody urine, frequent/painful urination, severe drowsiness, confusion, unusual changes in behavior, or hallucinations. Blood/bone marrow disorders can affect your body's ability to stop bleeding, or fight infection. Tell your doctor right away if you develop easy bruising/bleeding or signs of infection (such as sore throat that doesn't go away, fever, chills).
| Testicular germ cell tumor | |
| C62 | Malignant neoplasm of testis |
| C62.0 | Malignant neoplasm of undescended testis |
| C62.00 | Malignant neoplasm of unspecified undescended testis |
| C62.01 | Malignant neoplasm of undescended right testis |
| C62.02 | Malignant neoplasm of undescended left testis |
| C62.1 | Malignant neoplasm of descended testis |
| C62.10 | Malignant neoplasm of unspecified descended testis |
| C62.11 | Malignant neoplasm of descended right testis |
| C62.12 | Malignant neoplasm of descended left testis |
| C62.9 | Malignant neoplasm of testis, unspecified whether descended or undescended |
| C62.90 | Malignant neoplasm of unspecified testis, unspecified whether descended or undescended |
| C62.91 | Malignant neoplasm of right testis, unspecified whether descended or undescended |
| C62.92 | Malignant neoplasm of left testis, unspecified whether descended or undescended |
| 0-9 | A-Z |
|---|---|
| C62 | Malignant neoplasm of testis |
| C62.0 | Malignant neoplasm of undescended testis |
| C62.00 | Malignant neoplasm of unspecified undescended testis |
| C62.01 | Malignant neoplasm of undescended right testis |
| C62.02 | Malignant neoplasm of undescended left testis |
| C62.1 | Malignant neoplasm of descended testis |
| C62.10 | Malignant neoplasm of unspecified descended testis |
| C62.11 | Malignant neoplasm of descended right testis |
| C62.12 | Malignant neoplasm of descended left testis |
| C62.9 | Malignant neoplasm of testis, unspecified whether descended or undescended |
| C62.90 | Malignant neoplasm of unspecified testis, unspecified whether descended or undescended |
| C62.91 | Malignant neoplasm of right testis, unspecified whether descended or undescended |
| C62.92 | Malignant neoplasm of left testis, unspecified whether descended or undescended |
Formulary Reference Tool